Samsung Biologics Acquires GlaxoSmithKline's US Facility for $280 Million

Deep News04-01

Samsung Biologics, the biotechnology arm of Samsung Group, announced on Wednesday that it has acquired a US-based manufacturing plant from British pharmaceutical giant GlaxoSmithKline PLC for $280 million.

According to a press release issued by Samsung Biologics, the facility, located in Rockville, Maryland, possesses a production capacity of 60,000 liters for active pharmaceutical ingredients. This acquisition increases the company's total manufacturing capacity to 845,000 liters.

John Rim, President and CEO of Samsung Biologics, stated, "The addition of the Rockville plant enhances our ability to operate a geographically diversified production network."

As a contract development and manufacturing organization (CDMO), the company is committed to supporting its partners in delivering treatment solutions to patients worldwide. The newly acquired facility is expected to play a critical role in this effort.

Samsung Biologics indicated that it plans to make further investments to expand the plant's capacity and upgrade its technology. This move reinforces the company's long-term commitment to strengthening global supply chains and improving access to essential medicines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151023687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 13:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151023687","market":"sg","top_or_hot":-1,"title":"Samsung Biologics Acquires GlaxoSmithKline's US Facility for $280 Million","media":"Deep News","content":"<p>Samsung Biologics, the biotechnology arm of Samsung Group, announced on Wednesday that it has acquired a US-based manufacturing plant from British pharmaceutical giant GlaxoSmithKline PLC for $280 million.</p>\n<p>According to a press release issued by Samsung Biologics, the facility, located in Rockville, Maryland, possesses a production capacity of 60,000 liters for active pharmaceutical ingredients. This acquisition increases the company's total manufacturing capacity to 845,000 liters.</p>\n<p>John Rim, President and CEO of Samsung Biologics, stated, \"The addition of the Rockville plant enhances our ability to operate a geographically diversified production network.\"</p>\n<p>As a contract development and manufacturing organization (CDMO), the company is committed to supporting its partners in delivering treatment solutions to patients worldwide. The newly acquired facility is expected to play a critical role in this effort.</p>\n<p>Samsung Biologics indicated that it plans to make further investments to expand the plant's capacity and upgrade its technology. This move reinforces the company's long-term commitment to strengthening global supply chains and improving access to essential medicines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung Biologics Acquires GlaxoSmithKline's US Facility for $280 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung Biologics Acquires GlaxoSmithKline's US Facility for $280 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-01 13:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Samsung Biologics, the biotechnology arm of Samsung Group, announced on Wednesday that it has acquired a US-based manufacturing plant from British pharmaceutical giant GlaxoSmithKline PLC for $280 million.</p>\n<p>According to a press release issued by Samsung Biologics, the facility, located in Rockville, Maryland, possesses a production capacity of 60,000 liters for active pharmaceutical ingredients. This acquisition increases the company's total manufacturing capacity to 845,000 liters.</p>\n<p>John Rim, President and CEO of Samsung Biologics, stated, \"The addition of the Rockville plant enhances our ability to operate a geographically diversified production network.\"</p>\n<p>As a contract development and manufacturing organization (CDMO), the company is committed to supporting its partners in delivering treatment solutions to patients worldwide. The newly acquired facility is expected to play a critical role in this effort.</p>\n<p>Samsung Biologics indicated that it plans to make further investments to expand the plant's capacity and upgrade its technology. This move reinforces the company's long-term commitment to strengthening global supply chains and improving access to essential medicines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1151023687","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151023687","pubTimestamp":1775020822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Samsung Biologics, the biotechnology arm of Samsung Group, announced on Wednesday that it has acquired a US-based manufacturing plant from British pharmaceutical giant GlaxoSmithKline PLC for $280...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","GSK.UK":"葛兰素史克","GSKH":"GSK plc ADRhedged","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药"},"translate_title":"三星生物制品2.8亿美元收购葛兰素史克美国工厂","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":1,"GSKH":1,"GSK":1},"content_text":"Samsung Biologics, the biotechnology arm of Samsung Group, announced on Wednesday that it has acquired a US-based manufacturing plant from British pharmaceutical giant GlaxoSmithKline PLC for $280 million.\nAccording to a press release issued by Samsung Biologics, the facility, located in Rockville, Maryland, possesses a production capacity of 60,000 liters for active pharmaceutical ingredients. This acquisition increases the company's total manufacturing capacity to 845,000 liters.\nJohn Rim, President and CEO of Samsung Biologics, stated, \"The addition of the Rockville plant enhances our ability to operate a geographically diversified production network.\"\nAs a contract development and manufacturing organization (CDMO), the company is committed to supporting its partners in delivering treatment solutions to patients worldwide. The newly acquired facility is expected to play a critical role in this effort.\nSamsung Biologics indicated that it plans to make further investments to expand the plant's capacity and upgrade its technology. This move reinforces the company's long-term commitment to strengthening global supply chains and improving access to essential medicines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151023687","isCrawlerRequest":true}